10 Top Studies from IDWeek for Primary Care, In Case you Missed Them

IDWeek 2023, held from October 12-15, in Boston, MA, featured physician scientists covering topics from antibiotic stewardship to artificial intelligence and offered hundreds of new studies on influenza, COVID-19, respiratory syncytial virus, HIV/AIDs, meningococcal disease, herpes, fungal infection, vaccines, antimicrobials, and emerging pathogens.

There was a lot more, but in case you missed the meeting, this short slide show highlights 10 studies with findings that may influence primary care practice.

This study found that 1 dose of RSVPreF3 OA is efficacious against RSV-LRTD in adults aged ≥60 years over 2 full RSV seasons, as well as against severe RSV-LRTD, and in adults with advanced age, and with underlying comorbidities. Read more

^{Image ©Artur/stock.adobe.com}

In a cohort of adults aged ≥50 years hospitalized for acute respiratory infection, those who were subsequently diagnosed with respiratory syncytial virus were more likely to be women, be immunocompromised, and to have traveled within the previous 2 weeks. More here

_{^{Image ©NAMPIX/stock.adobe.com}}

The study identified disparities in coverage related to age, race, ethnicity, household income, insurance status, and prior influenza vaccination. Among the study’s key findings—while being fully vaccinated increased with age to a high of 63.4%, full vaccination across age groups in this population was consistently lower than national coverage estimates. Read more

_{©MohamadFaizal/stock.adobe.com}

A booster dose of the mRNA-1273 vaccine provided significant additional protection against COVID-19 infection during the pandemic’s Delta and Omicron waves, with the observed effects much greater among adults aged 65 years and older. Read more

^{©freshidea/stock.adobe.com}

The intranasal delivery route is meant to mimic natural infection and to induce a localized immune response in the nasal cavity, wrote authors of the first-in-human study. There currently are no approved live attenuated or intranasal vaccines against COVID-19. Read more.

^{©freshidea/stock.adobe.com}

Researchers say that although they did not reach statistical significance, the findings demonstrate the capacity to use an existing influenza vaccine effectiveness network to study a large immunocompromised population. Read more

^{©Leigh Prather/stock.adobe.com}

Immune response in older adults after receiving both vaccines in the same visit was noninferior to sequential administration and the safety profile was acceptable. Read more

^{©Kateryna_Kon/stock.adobe.com}

In a new study of adults who received 3 doses of measles-mumps-rubella (MMR) vaccine, measles antibody levels declined over time, while rubella antibody levels remained stable and protective. Read more

^{©Sherry Yates Young/shutterstock.com}

A modeling study projected an annual reduction of nearly 25 000 infant hospitalizations and 46 000 ED encounters following maternal vaccination against RSV. Read more

^{©yepifanohvahelen/stock.adobe.com}

Using a stochastic model to estimate the impact of influenza vaccination on severe outcomes in older adults, investigators showed a significant reduction in cardiovascular, respiratory, and other complications and also that vaccination with an adjuvanted vaccine could avert the majority of influenza-related hospitalizations and deaths. Read more

^{©Studio Romantic/stock.adobe.com}

PreviousNext